Ruth Itzhaki on Toronto: In Small Trial, IVIg Slows Brain Shrinkage
COMMENT The trial of IVIg (Gammagard) for treating AD patients was done with the aim of augmenting their relatively low level of anti-Aβ antibodies, thereby enhancing the clearance of Aβ. We wonder if, instead, the beneficial effect of IVIg might have been throug